Inflammation is associated with adverse cardiovascular events. Data from recent trials suggest that colchicine reduces the risk of cardiovascular events. In this multicenter trial with a 2-by-2 ...
Empagliflozin improves cardiovascular outcomes in patients with heart failure, patients with type 2 diabetes who are at high cardiovascular risk, and patients with chronic kidney disease. The safety ...
Myocardial infarction (MI) causes millions of deaths worldwide. Though there have been advances in the survival rates following ST-elevation MI (STEMI), survivors often develop heart failure due to ...
Myocardial ischemia is a drop in blood flow to the heart. Myocardial infarction, or heart attack, occurs when death or damage occurs in the muscle tissue of the heart due to low blood supply. The ...
The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a ...
Empagliflozin stabilizes kidney function and reduces heart failure risk post-myocardial infarction, with eGFR remaining stable over 24 months. The EMPACT-MI trial confirmed empagliflozin's safety when ...
Credit: Getty Images A discussion of the use of beta-blocker therapy following AMI, with Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD. Beta blockers have long been included in the ...
Presenter: Stuart J. Connolly, MD, McMaster University (Hamilton, Ontario, CANADA) and Stefan H. Hohnloser, MD, J.W. Goethe University (Frankfurt, Germany) Large randomized clinical trials have ...
Advanced CKD in AMI patients receiving MCS is associated with increased mortality, complications, and resource utilization compared to those without advanced CKD. ESRD patients undergoing CABG after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results